Department of Reproductive Medicine, Affiliated Hospital of Weifang Medical University, 261031, Weifang, Shandong, China.
Department of Medical Laboratory, Affiliated Hospital of Weifang Medical University, 261031, Weifang, Shandong, China.
Mol Cell Biochem. 2020 Dec;475(1-2):107-118. doi: 10.1007/s11010-020-03863-y. Epub 2020 Aug 10.
Long noncoding RNAs (lncRNAs) have been shown to be implicated in acetaminophen (APAP)-induced liver injury (AILI). We applied this study to investigate the role and functional mechanism of KCNQ1 overlapping transcript 1 (KCNQ1OT1) in AILI. The AILI model was established by APAP treatment in mice. The liver injury was preliminarily evaluated by ALT and AST activities via the detection kits. The quantitative real-time polymerase chain reaction (qRT-PCR) was exploited for detecting the expression of KCNQ1OT1, microRNA-122-5p (miR-122-5p), and carboxylesterase 2 (CES2). Protein levels were analyzed via Western blot. 3-(4, 5-dimethylthiazol-2-y1)-2, 5-diphenyl tetrazolium bromide (MTT) assay, and flow cytometry were separately applied to determine cell proliferation and apoptosis rate. Inflammation was assessed by enzyme-linked immunosorbent assay (ELISA). Dual-luciferase reporter assay was implemented to testify the intergenic combination. The function of KCNQ1OT1 in vivo was explored through KCNQ1OT1 knockdown in mice. APAP triggered the downregulation of KCNQ1OT1 and CES2 in mice serums. KCNQ1OT1 upregulation could relieve the AILI in HepaRG cells, which were abrogated by CES2 downregulation. KCNQ1OT1 served as a sponge of miR-122-5p and miR-122-5p directly targeted CES2. KCNQ1OT1 overexpression abated the AILI through the miR-122-5p/CES2 axis in HepaRG cells in vitro and mice in vivo. The collective results clarified that KCNQ1OT1 weakened the AILI in vitro and in vivo by the miR-122-5p/CES2 axis, providing an explicit molecular mechanism and selectable therapeutic strategy of AILI.
长链非编码 RNA(lncRNA)已被证明与对乙酰氨基酚(APAP)诱导的肝损伤(AILI)有关。我们应用这项研究来探讨 KCNQ1 重叠转录本 1(KCNQ1OT1)在 AILI 中的作用和功能机制。通过 APAP 处理在小鼠中建立 AILI 模型。通过检测试剂盒检测 ALT 和 AST 活性初步评估肝损伤。利用定量实时聚合酶链反应(qRT-PCR)检测 KCNQ1OT1、microRNA-122-5p(miR-122-5p)和羧酸酯酶 2(CES2)的表达。通过 Western blot 分析蛋白水平。3-(4,5-二甲基噻唑-2-y1)-2,5-二苯基四氮唑溴盐(MTT)测定法和流式细胞术分别用于测定细胞增殖和凋亡率。通过酶联免疫吸附测定(ELISA)评估炎症。双荧光素酶报告基因检测用于验证基因间组合。通过在小鼠中敲低 KCNQ1OT1 来探索 KCNQ1OT1 在体内的功能。APAP 触发小鼠血清中 KCNQ1OT1 和 CES2 的下调。KCNQ1OT1 的上调可以缓解 HepaRG 细胞中的 AILI,而 CES2 的下调则可以消除这种作用。KCNQ1OT1 作为 miR-122-5p 的海绵,miR-122-5p 直接靶向 CES2。KCNQ1OT1 过表达通过 miR-122-5p/CES2 轴在 HepaRG 细胞中减轻了 AILI,并且在体外和体内的小鼠中也减轻了 AILI。总的来说,这些结果表明,KCNQ1OT1 通过 miR-122-5p/CES2 轴在体外和体内减弱了 AILI,为 AILI 提供了明确的分子机制和可选的治疗策略。